SRA1 (steroid receptor RNA activator 1) is a functional long non-coding RNA that acts as a transcriptional coactivator for steroid receptors through both ligand-independent and ligand-dependent mechanisms [UniProt]. At the molecular level, SRA1 enhances steroid receptor-mediated transactivation by modulating the N-terminal (AF-1) and steroid-binding (AF-2) domains of steroid receptors, while promoting cellular proliferation, differentiation, and apoptosis [UniProt]. In disease pathology, SRA1 overexpression is associated with poor clinical outcomes in ovarian cancer; 55% of ovarian carcinomas show elevated SRA1 expression, which correlates with increased tumor size, grade, stage, and decreased overall and progression-free survival, establishing SRA1 as an independent prognostic biomarker 1. Additionally, SRA1 genetic variants show associations with polycystic ovary syndrome (PCOS) susceptibility, with the rs10463297 SNP showing protective effects, and specific haplotype combinations conferring increased disease risk 2. SRA1 has also emerged as a biomarker in systemic lupus erythematosus disease exacerbation assessment within a nine-protein combination demonstrating robust diagnostic performance (AUC=0.990) 3. Clinically, these findings suggest SRA1 may serve as both a prognostic indicator in cancer and an immunological biomarker in autoimmune conditions, representing a potential therapeutic target.